United Asset Strategies’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.68M | Buy |
14,614
+4,604
| +46% | +$991K | 0.26% | 77 |
|
|
2026
Q1 | $2.18M | Buy |
10,010
+159
| +2% | +$35.3K | 0.17% | 96 |
|
|
2025
Q4 | $2.25M | Buy |
9,851
+134
| +1% | +$30.5K | 0.17% | 97 |
|
|
2025
Q3 | $2.25M | Sell |
9,717
-134
| -1% | -$27.3K | 0.18% | 94 |
|
|
2025
Q2 | $1.83M | Sell |
9,851
-177
| -2% | -$32.9K | 0.16% | 106 |
|
|
2025
Q1 | $2.1M | Sell |
10,028
-3,811
| -28% | -$741K | 0.2% | 97 |
|
|
2024
Q4 | $2.46M | Sell |
13,839
-102
| -0.7% | -$18.8K | 0.23% | 85 |
|
|
2024
Q3 | $2.75M | Buy |
13,941
+422
| +3% | +$78.8K | 0.26% | 76 |
|
|
2024
Q2 | $2.32M | Sell |
13,519
-698
| -5% | -$116K | 0.23% | 83 |
|
|
2024
Q1 | $2.59M | Buy |
14,217
+298
| +2% | +$51.4K | 0.26% | 77 |
|
|
2023
Q4 | $2.16M | Buy |
13,919
+1,772
| +15% | +$258K | 0.24% | 79 |
|
|
2023
Q3 | $1.81M | Buy |
12,147
+150
| +1% | +$22K | 0.23% | 90 |
|
|
2023
Q2 | $1.62M | Sell |
11,997
-4,559
| -28% | -$669K | 0.2% | 102 |
|
|
2023
Q1 | $2.64M | Buy |
16,556
+236
| +1% | +$36.1K | 0.35% | 68 |
|
|
2022
Q4 | $2.64M | Buy |
16,320
+1,095
| +7% | +$168K | 0.37% | 69 |
|
|
2022
Q3 | $2.04M | Buy |
15,225
+466
| +3% | +$66.9K | 0.31% | 73 |
|
|
2022
Q2 | $2.26M | Buy |
14,759
+138
| +0.9% | +$21.1K | 0.33% | 74 |
|
|
2022
Q1 | $2.37M | Sell |
14,621
-37,440
| -72% | -$5.44M | 0.3% | 72 |
|
|
2021
Q4 | $7.05M | Buy |
52,061
+4,907
| +10% | +$580K | 0.84% | 44 |
|
|
2021
Q3 | $5.09M | Buy |
47,154
+2,755
| +6% | +$315K | 0.66% | 47 |
|
|
2021
Q2 | $5M | Buy |
44,399
+3,431
| +8% | +$386K | 0.67% | 49 |
|
|
2021
Q1 | $4.43M | Buy |
40,968
+15,996
| +64% | +$1.71M | 0.64% | 51 |
|
|
2020
Q4 | $2.68M | Sell |
24,972
-33
| -0.1% | -$3.17K | 0.42% | 64 |
|
|
2020
Q3 | $2.19M | Sell |
25,005
-869
| -3% | -$81.8K | 0.4% | 62 |
|
|
2020
Q2 | $2.54M | Buy |
+25,874
| New | +$2.28M | 0.5% | 59 |
|
|
2016
Q4 | – | Sell |
-3,457
| Closed | -$218K | – | 149 |
|
|
2016
Q3 | $218K | Sell |
3,457
-323
| -9% | -$20.9K | 0.08% | 127 |
|
|
2016
Q2 | $234K | Buy |
+3,780
| New | +$230K | 0.09% | 123 |
|
|
2015
Q3 | – | Sell |
-46,178
| Closed | -$3.1M | – | 127 |
|
|
2015
Q2 | $3.1M | Buy |
46,178
+158
| +0.3% | +$10.3K | 1.39% | 26 |
|
|
2015
Q1 | $2.98M | Buy |
46,020
+42,340
| +1,151% | +$2.56M | 1.38% | 27 |
|
|
2014
Q4 | $241K | Hold |
3,680
| – | – | 0.1% | 108 |
|
|
2014
Q3 | $213K | Buy |
+3,680
| New | +$204K | 0.1% | 120 |
|
Other funds holding ABBV
ECSS
ATO
United Asset Strategies's ABBV Position: Q2 2026 in Review
United Asset Strategies increased its AbbVie (ABBV) stake by 46% in Q2 2026, buying an estimated $991K and bringing the position to 14,614 shares worth $3.68M. The position accounts for 0.26% of the portfolio, ranked #77.
United Asset Strategies first reported a position in ABBV in Q3 2014 and has held it in 31 quarters since. The position peaked at $7.05M in Q4 2021. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- United Asset Strategies held 14,614 shares of AbbVie worth $3.68M as of Q2 2026.
- United Asset Strategies bought 4,604 AbbVie shares in Q2 2026, an estimated $991K.
- AbbVie made up 0.26% of United Asset Strategies's portfolio in Q2 2026, its #77 holding.
- United Asset Strategies first reported a position in AbbVie in Q3 2014 and has held it in 31 quarters since.
- United Asset Strategies's AbbVie position peaked at $7.05M in Q4 2021.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on United Asset Strategies's 13F filing for Q2 2026, filed 13 Jul 2026.